DK1385577T3 - Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi - Google Patents

Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi

Info

Publication number
DK1385577T3
DK1385577T3 DK02719751T DK02719751T DK1385577T3 DK 1385577 T3 DK1385577 T3 DK 1385577T3 DK 02719751 T DK02719751 T DK 02719751T DK 02719751 T DK02719751 T DK 02719751T DK 1385577 T3 DK1385577 T3 DK 1385577T3
Authority
DK
Denmark
Prior art keywords
receptor antagonists
benign prostatic
prostatic hyperplasia
antagonists against
against benign
Prior art date
Application number
DK02719751T
Other languages
Danish (da)
English (en)
Inventor
Susanne Buser
Anthony P D W Ford
Barbara Lenz
Andrew John Sleight
Pierre Vankan
Torsten Hoffmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1385577T3 publication Critical patent/DK1385577T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02719751T 2001-04-23 2002-02-02 Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi DK1385577T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01109853 2001-04-23

Publications (1)

Publication Number Publication Date
DK1385577T3 true DK1385577T3 (da) 2006-08-21

Family

ID=8177209

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02719751T DK1385577T3 (da) 2001-04-23 2002-02-02 Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi

Country Status (17)

Country Link
US (1) US20030004157A1 (sh)
EP (1) EP1385577B1 (sh)
JP (1) JP4146730B2 (sh)
KR (1) KR100599134B1 (sh)
CN (1) CN100398106C (sh)
AR (1) AR035935A1 (sh)
AT (1) ATE323531T1 (sh)
AU (1) AU2002250876B2 (sh)
BR (1) BR0209151A (sh)
CA (1) CA2444395C (sh)
DE (1) DE60210760T2 (sh)
DK (1) DK1385577T3 (sh)
ES (1) ES2261657T3 (sh)
MX (1) MXPA03009720A (sh)
PT (1) PT1385577E (sh)
WO (1) WO2002085458A2 (sh)
ZA (1) ZA200308110B (sh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089802A2 (en) * 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
NZ541243A (en) 2003-01-31 2008-04-30 Hoffmann La Roche New crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
DK1643998T3 (da) * 2003-07-03 2007-12-27 Hoffmann La Roche NK1/NK3-antagonister til behandling af skizofreni
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
MX2007000198A (es) 2004-07-06 2007-03-15 Hoffmann La Roche Proceso para la preparacion de derivados de carboxamida-piridina utilizados como intermediarios en la sintesis de antagonistas del receptor nk-1.
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
EP2281556A1 (en) 2005-02-25 2011-02-09 F. Hoffmann-La Roche AG Tablets with improved drugs substance dispersibility
KR20150041174A (ko) 2005-11-08 2015-04-15 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
BRPI0807972A2 (pt) 2007-01-24 2014-06-10 Glaxo Group Ltd Composições farmacêuticas compreendendo 3,5-diamino-6-(2,3-diclofenil)-l,2,4-triazina ou r(-)-2,4-diamino-5-(2,3-diclorofenil)-6-fluorometilpirim idina e uma nk1
AU2008251504B2 (en) 2007-05-09 2013-07-18 Vertex Pharmaceuticals Incorporated Modulators of CFTR
DK2639224T3 (en) 2007-12-07 2016-10-17 Vertex Pharma A process for the preparation of cycloalkylcarboxiamido-pyridinbenzoesyrer
EP3170818B1 (en) 2007-12-07 2020-02-19 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
WO2009108657A2 (en) 2008-02-28 2009-09-03 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
EP2409977A4 (en) 2009-03-17 2012-09-26 Daiichi Sankyo Co Ltd AMIDE DERIVATIVE
WO2010119347A1 (en) * 2009-04-14 2010-10-21 Helsinn Healthcare S.A. Netupitant for use in treating bladder dysfunction
EP2493299A4 (en) * 2009-10-29 2013-04-17 Merck Sharp & Dohme TERTIARY AMIDOREXIN RECEPTOR ANTAGONISTS
HUE056525T2 (hu) 2010-04-07 2022-02-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása
WO2015068744A1 (ja) 2013-11-08 2015-05-14 キッセイ薬品工業株式会社 カルボキシメチルピペリジン誘導体
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
DK3221692T3 (da) 2014-11-18 2021-08-23 Vertex Pharma Fremgangsmåde til udførsel af tests med høj kapacitet ved hjælp af højtryksvæskekromatografi
CA3089662A1 (en) * 2018-02-02 2019-08-08 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Parenteral formulations and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
FR2729951B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
BR9811819A (pt) * 1997-08-06 2000-08-15 Lilly Co Eli 2-acilaminopropanaminas como antagonistas receptores de taquicinina
TR200000291T2 (tr) * 1997-08-06 2000-07-21 Eli Lilly And Company Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
DK1394150T3 (da) * 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
WO2000067742A2 (en) * 1999-05-05 2000-11-16 Warner-Lambert Company Use of gaba analogues for the modulation of substance p
DK1303490T3 (da) * 2000-07-14 2008-08-25 Hoffmann La Roche N-oxider som NK1-receptorantagoniskprodugs af 4-phenyl-pyridinderivater
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Also Published As

Publication number Publication date
AU2002250876B2 (en) 2005-03-03
US20030004157A1 (en) 2003-01-02
ZA200308110B (en) 2005-03-30
DE60210760T2 (de) 2006-11-23
CN100398106C (zh) 2008-07-02
JP4146730B2 (ja) 2008-09-10
CA2444395C (en) 2010-12-21
CA2444395A1 (en) 2002-10-31
EP1385577A2 (en) 2004-02-04
KR100599134B1 (ko) 2006-07-12
BR0209151A (pt) 2004-07-13
MXPA03009720A (es) 2004-01-29
DE60210760D1 (de) 2006-05-24
WO2002085458A3 (en) 2003-10-30
EP1385577B1 (en) 2006-04-19
KR20040007503A (ko) 2004-01-24
JP2004529931A (ja) 2004-09-30
CN1503684A (zh) 2004-06-09
ATE323531T1 (de) 2006-05-15
AR035935A1 (es) 2004-07-28
PT1385577E (pt) 2006-08-31
ES2261657T3 (es) 2006-11-16
WO2002085458A2 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
DK1385577T3 (da) Anvendelse af NK-1-receptorantagonister mod godartet prostatahyperplasi
DK1278350T3 (da) Autentificering af verificering for mobilbrugere
DK1339678T3 (da) Selektive agonister til EP4-receptor til behandling af osteoporose
DK1307181T3 (da) Hidtil ukendte sammensætninger af minoxidil
IS6289A (is) thríhringja hindrar af poly (ADP-ribosa) polymerösum
NO20053783D0 (no) Behandling av godartet prostatahyperplasi
DE60120419D1 (de) 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten
DK1438306T3 (da) Derivater af UK-2A
LV12770B (lv) Poli(adp-ribozo) polimerazu tricikliskie inhibitori
DK1505998T3 (da) Forbedret anvendelse af hop-syrer som antimikrobielle midler
DK1157005T3 (da) 3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister
DK1170288T3 (da) Diphenylurinstofderivater og deres anvendelse som alfa2/5-HT2c-antagonister
DK1373256T3 (da) CCR5-antagonister, der er nyttige til behandling af AIDS
DE60212156D1 (de) Reibungsdämpfendes bein
DK1458447T3 (da) Kombination af cytokrom-p450-beroende proteasinhibitorer
DK1354027T3 (da) Stabilisering af drikkevarer
DE60222693D1 (de) Nk1-antagonisten
NO20041968L (no) Anvendelse av cystationin
DK1276721T3 (da) Methylering af indolforbindelser under anvendelse af dimethylcarbonat
DK1296961T3 (da) 1,4-diazepan-2,5-dionderivater og anvendelse deraf som NK-1-receptorantagonister
IS2725B (is) Inndælingarlausn sem samanstendur af LHRH mótlyfi
DK1408964T3 (da) Hidtil ukendt anvendelse af 2-5-(4-fluorphenyl)-3-pyridylmethylaminomethyl-chroman og fysiologisk acceptable salte deraf
NO20023785L (no) Vanndispergerbar formulering av paroxetin
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
ATE370932T1 (de) Ccr-3-rezeptorantagonisten vii